A Two-Stage Injection Technique and Dose-Ranging Study Using High-Dose AbobotulinumtoxinA for Treating Platysmal...

Area of Science:

• Aesthetics
• Dermatology
• Neurology

Background:

• AbobotulinumtoxinA (aboBoNT-A) is recognized for treating platysmal banding.
• This study investigates a novel 2-stage injection protocol with higher doses of aboBoNT-A.

Purpose of the Study:

• To evaluate the efficacy and safety of a standardized 2-stage injection technique using high doses of aboBoNT-A for platysmal banding.
• To compare two different high-dose regimens of aboBoNT-A.

Main Methods:

• A randomized, double-blinded, dose-ranging study was conducted.
• Adults with moderate-to-severe platysmal bands received either 120 U (Cohort 1) or 180 U (Cohort 2) of aboBoNT-A, with an optional 90 U touch-up.
• Higher on-label concentration (1.5 mL/300 units) was used to minimize spread, with 5-month follow-up and assessments via Investigator Live Assessment (ILA) and Subject Live Assessment (SLA).

Main Results:

• Both cohorts showed high responder rates (100% and 90%) at month 1.
• Cohort 2 (180 U) demonstrated superior improvement in platysmal band severity by both ILA and SLA.
• Cohort 2 also exhibited a longer duration of response, with only transient neck weakness reported in 3 subjects.

Conclusions:

• A standardized 2-stage injection technique with higher doses of aboBoNT-A is effective for moderate-to-severe platysmal banding.
• The technique maintains a good safety profile, enhanced by using concentrated on-label volumes and a touch-up injection.
• This approach offers an effective treatment option for platysmal banding with favorable outcomes.